New cocktail of three drugs targets Hard-to-Treat breast cancer
NCT ID NCT05458674
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing whether a combination of three drugs—tucatinib, eribulin, and trastuzumab—is safe and effective for people with advanced HER2+ breast cancer that has not responded to prior treatments. The study will enroll 30 participants and measure tumor shrinkage, side effects, and how long the cancer stays under control. It is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tucatinib (TUKYSA), eribulin (HALAVEN), and trastuzumab (HERCEPTIN)
What this could lead to
If successful, this three-drug combination could offer a new treatment option for people with advanced HER2+ breast cancer who have already tried other therapies.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 30 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Care Northwest
RECRUITINGSpokane Valley, Washington, 99216, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
George Washington Medical Faculty Associates
RECRUITINGWashington D.C., District of Columbia, 20037, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
New Mexico Cancer Care Alliance
RECRUITINGAlbuquerque, New Mexico, 87131, United States
Contact Email: •••••@•••••
Contact
-
Swedish Cancer Institute
RECRUITINGIssaquah, Washington, 98029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact